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Abstract
We calculate measures of hierarchy in gene and tissue networks of breast cancer
patients. We find that the likelihood of metastasis in the future is correlated with in-
creased values of network hierarchy for expression networks of cancer-associated genes,
due to correlated expression of cancer-specific pathways. Conversely, future metasta-
sis and quick relapse times are negatively correlated with values of network hierarchy
in the expression network of all genes, due to dedifferentiation of gene pathways and
circuits. These results suggest that hierarchy of gene expression may be useful as an
additional biomarker for breast cancer prognosis.
1 Introduction
As cancer develops, there are changes in patterns of gene expression. There are several
examples where a defect in a single gene causes a genetic predisposition to developing
cancer, for example the BRCA1 and BRCA2 genes in breast cancer [1–3]. In general,
however, the development of cancer is the result of correlated networks of gene expression
networks gone awry. That is, cancer is a systemic disease, and changes in fidelity of gene
expression are signatures of cancer. In some cases, changes in gene expression networks can
determine disease outcome [4–12]. Thus, structural features of gene expression networks
may be ‘biomarkers’ that can predict the probability of a patient developing or surviving
cancer.
We here focus on the relation between metastasis and the structure of networks relevant
to cancer. Metastasis is the leading cause of cancer mortality [13]. Once metastasis has
occurred, the chance of patient survival drops dramatically [14]. Clinicians use prognostic
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factors such as age or size of tumor at the time of tumor removal to predict the risk of
recurrence [14]. Here, we present an analysis of the relation between breast cancer prognosis
and hierarchical structure in correlations of cancer gene expression networks. We will show
that these measures of hierarchy in correlations of gene expression distinguish between
non-metastatic and metastatic patient populations. We will also show that these measures
of hierarchy in gene expression are predictive of average time of relapse in breast cancer
patients.
We are motivated to study hierarchy of gene expression by theory that relates hierarchy
to environmental stress and variability [15–17]. This theory shows that when a system is
placed in a more variable environment, it will tend to become more hierarchical, if it has
the ability to do so. This occurs because hierarchy will tend to increase the adaptability
of the system. This theory predicts that expression networks of cancer-associated genes
may be more hierarchical in more aggressive tumors or during metastasis due to increased
correlations in cancer-associated gene pathways. Conversely, measures of hierarchy in the
network of all genes will likely decrease for more aggressive tumors or during metastasis,
since cancer progression is a dedifferentiation of the entire gene network.
Measures of modularity have been defined for cancer gene and protein interaction networks.
Carro et al. identified transcriptional modules in a context-specific regulatory network
that controls expression of the mesenchymal signature associated with metastatic outcome
[5, 18]. This result identified a small regulatory module that was part of the mechanism
that controlled an important phenotypic state in cancer cells. Chuang et al. extracted sub-
networks from protein interaction databases and found subnetworks that were significantly
enriched with cancer susceptibility genes [5]. Comparison of normal and colon cancer gene
networks identified changes in network structure. Oslund et al. have ranked cancer genes
candidates by local network structures, such as neighbor annotation [19]. Yu et al. have
used signature analysis to identify multiple breast cancer modules [20]. Taylor et al. used
co-expression of hub proteins and their partners to identify whether interactions are context
specific, i.e. interacting proteins are not always co-expressed, or constitutive, i.e. interact-
ing proteins are always co-expressed [4, 5]. They found that during tumor progression,
hub proteins are disorganized by loss of coordinated co-expression of components. Thus,
changes in the correlation of tumor interactomes were shown to be a prognostic signature
in cancer. Other studies have also demonstrated that modularity in the protein-protein
interaction network or cell-cell interaction network is an important indicator for cancer
prognosis [4] or tumor metastasis [21].
We here quantify the hierarchical structure in cancer networks, generalizing the concept of
modularity. Modularity is one measure of the structure of cancer networks. Hierarchy is
a measure of the modularity that exists in cancer networks at different scales. The rest of
the paper is organized as follows. In section 2 we describe how we created gene and tissue
networks from gene expression data previously collected from a population of metastatic
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and non-metastatic patients. In section 3, we show that hierarchy in networks of cancer-
associated genes is positively correlated with metastasis due to activation of cancer specific
pathways. Conversely, for networks of all genes, we show that a measure of hierarchy is
negatively correlated with metastasis and early recurrence times due to dedifferentiation.
We discuss these results in section 4. We conclude in section 5.
2 Methods
We used gene expression profiles of breast cancer patients to construct the networks. The
expression profiles were previously obtained from 286 women with lymph node negative
disease who had not received adjuvant systemic treatment [22, 23]. In that experiment,
total RNA of frozen tumor samples was hybridized to Affymetrix Human U133a GeneChips.
Expression values were calculated by the Affymetrix GeneChip analysis software MAS 5.0.
Of the many genes analyzed, 76 cancer associated genes were identified as predictive of
metastasis. Relapse and metastasis of the patients were examined during follow-up visits
within 5 years [22].
Of these patients, 179 did not relapse and metastasize, and 107 were identified to have
developed a distant metastasis during a follow up visit within 5 years[22]. We seek to
distinguish using the data at year 0, the 179 patients that were disease free after extended
treatment from the 107 patients that developed distant metastases within 5 years. We
constructed cancer networks with two types of nodes: cancer-associated genes or tissue
types.
2.1 Gene Networks
To construct networks of the first type, we defined a network with nodes of cancer-
associated genes. A total of 76 genes were previously identified as markers that discrimi-
nated patients who developed distant metastases from those remaining metastasis-free for
5 years [22]. We use these 76 cancer-associated genes as the nodes of our network. The
links between pairs of nodes were defined by the Pearson correlation coefficient of the two
gene expression values:
lα,β =
n∑
i
(Pi,α − µα)(Pi,β − µβ)
σασβ
(1)
From this definition lα,β is symmetric in α and β, and so the graph is undirected. Here
Pi,α is the expression data of gene α for patient i from [22], µα is the average expression
value for gene α for the n patients, and σα is the standard deviation of expression value
of gene α for the n patients. The expression value, Pi,α, is a measure of the abundance
of the transcript reported by Affymetrix GeneChip analysis software MAS 5.0, scaled to
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a standard target intensity [22]. To make comparisons between the non-metastatic and
the metastatic groups, which contain different number of patients, we randomly chose 40
patients each from the non-metastatic group and metastatic group. This random selection
of patients mitigates bias due to differing patient group sizes. We repeated the procedure
100 times, which gives us 100 networks for the metastatic group and 100 networks for the
non-metastatic group. Error bars are calculated from this bootstrapping procedure.
2.2 Tissue Networks
Networks of the second type are based upon tissues. We used tissue expression data
previously collected for 79 human tissues [24, 25]. We are motivated to study the tissue
network because during metastasis cancer spreads between and through different tissue
types. The systemic nature of metastasis suggests gene expression in different tissue types
may be informative to cancer prognosis. The tissue network is built with tissues as nodes
and correlation of gene expression between different tissues as the link values. Specifically,
we treat each tissue as a node and built a 79 × 79 tissue network, where the link value
between tissue i and tissue j is weighted by the expression data of patient k, Pk,α from [22]
to calculate a Pearson correlation coefficient:
lki,j =
〈
(Ti,αPk,α − µi,k)(Tj,αPk,α − µj,k)
σi,kσj,k
〉
α
(2)
This definition is symmetric in i and j, and so the network is undirected. Here α is the
gene, Ti,α is the expression level of gene α in tissue i from [24], µi,k is the average value
of Ti,αPk,α over all the available genes, and σi,k is the standard deviation of Ti,αPk,α.
The expression value, Ti,α, is a measure of the abundance of the transcript reported by
Affymetrix GeneChip analysis software MAS 5.0, normalized by a global median setting
[24]. We set a cutoff for using tissue expression data, from 10% to 90%. Values of Ti,α
falling below the cutoff are set to zero. BioGPS was used to map the gene names from
the tissue data set [24] and the breast cancer data set [22] into NCBI IDs. Eq. (2) is an
approximation to an ideal of a dataset with expression data for each tissue type from each
breast cancer patient. We will show that structure in the network defined by Eq. (2) has
predictive power for probability of metastasis within 5 years.
2.3 The CCC
To quantify structure in these networks, we define a measure of the hierarchy in the net-
works. Since a tree topology is the archetypal hierarchical structure, we use a measure
of hierarchy that quantifies how tree-like the network is. To calculate this measure of hi-
erarchy, we first computed the distance matrix defined by the network. We defined the
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distance between node i and j, dij , by the square root of the commute time. The commute
time is the expected time it takes a random walker to travel from one of the nodes to an
other and back [26]. The commute time between nodes i and j depends not only on the
link value but also on all the other possible paths between nodes i and j. Note that the
commute time between two nodes of a weighted graph decreases when the number of paths
connecting the two nodes increases. The commute time between two nodes also decreases
when the length of any path connecting the nodes decreases. These properties make the
commute time well suited for clustering tasks. To define the commute time, we let L de-
note the graph Laplacian, defined as L = D − A, where A is the matrix of links, A = l in
Eq. (1) or (2), and the diagonal matrix D = diag(Ai), with Ai =
∑
j Aij . The commute
time is obtained from L+, the Moore-Penrose pseudoinverse of the graph Laplacian L by
[27]
n(i, j) = VG(ei − ej)TL+(ei − ej). (3)
Here (ei)j = δij and VG =
∑
ij aij . Since L+ is symmetric and positive semidefinite,
dij =
√
n(i, j) is a Euclidean distance metric, called the Euclidean commute time (ECT)
distance.
We next applied the average linkage hierarchical clustering algorithm to construct the tree
topology that best fit the cancer network [28]. This method takes the matrix of distances
between all nodes of the network, dij , and produces a tree topology that best reproduces
those distances. The construction of the tree from the network by this algorithm is unique,
and approximately optimal in reproducing the distances. The distances of the tree topology
are denoted by cij . The tree topology has the same nodes as the original network, but
different links. We calculate the correlation between the original data and the best fitting
tree, which gave the cophenetic correlation coefficient (CCC). The greater the correlation,
the more hierarchical are the data. The nodes and links of the cancer network define the
original data. The tree that best fits the data defines an approximation to the original
network, termed the cophenetic matrix. The elements of the cophenetic matrix are the
heights where two network nodes become members of the same cluster in the tree, see
Figure 1. Distance between nodes in the best fitting tree are obtained from the height of
the common bifurcation point between those nodes. This height is the cophenetic element
of these two nodes, cij . The correlation between this cophenetic matrix constructed from
the best fitting tree and the original data distances is the CCC. The CCC is a measure
of similarity between the original data and the cophenetic matrix. The CCC is defined
as
CCC =
∑
i<j(dij − d)(cij − c)√
(
∑
i<j(dij − d)2
∑
i<j(cij − c)2
(4)
Here d is the average of the distances in the original network, dij , and c is the average of
the tree distances, cij .
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Figure 1: An illustration of how the CCC is calculated, on two networks. Distances between
each pair of nodes in the network are calculated by the Euclidean commute time distance,
i.e. the square root of the average round trip time from one node to the other node and
back. For each network, a tree best representing the network is constructed by the average
linkage hierarchical clustering algorithm. The distance between two nodes in the tree (y-
axis above) is the height above the baseline at which two nodes are joined in the tree
topology. To quantify the match between the tree and the original network, we calculated
the correlation between the distances in the network and the distances in the tree. This
correlation is termed the CCC. The more hierarchical the network, the greater the value
of the CCC.
3 Results
3.1 Cancer-Associated Gene Network
For the network of cancer-associated genes, we take the 76 cancer-associated genes as
the nodes, with link values from Eq. 1. We built a network by constructing a bootstrap
sample of patients from either the non-metastatic outcome or the metastatic outcome
groups. We calculated the average CCC value for many 40-person networks extracted
from the bootstrap sample. The bootstrap method was then used to calculate the overall
average CCC and standard error of this average. Figure 2a shows the result: hierarchy
of the cancer-associated gene network is greater in the metastatic group than in the non-
metastatic group.
We compared these results to those from random networks. We built 100 random net-
works of the same size and total number of edges as the cancer-associated network, then
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Figure 2: a) The CCC measure of hierarchy in the network of cancer-associated genes for
the metastatic and non-metastatic patient groups. We randomly choose 40 patients from
each group to construct the two networks. The bootstrap method was used to calculate the
averages and standard errors, shown by error bars. Data are from [22]. This result shows
that the network of cancer-associated genes is more hierarchical in the metastatic group.
b) The normalized CCC in the network of cancer-associated genes for the metastatic and
non-metastatic patient groups.
randomly reassigned the link values in the network. We define a normalized CCC as
CCCnorm = (CCC − CCCrand)/(1− CCCrand), where CCC is the value of the real cancer-
associated network, and CCCrand is the average CCC value of the randomized network.
We computed the z-score of the cancer-associated network CCC relative to the distri-
bution of CCC values of the random networks of the same size and sparsity, ZCCC =
(CCC − CCCrand)/σrand. We found ZCCC = 1.64 and ZCCC = 2.14 for the cancer-
associated gene networks in non-metastatic and metastatic patient groups compared to
randomly rewired networks.
To compare the network structure between 76 cancer-associated genes with the network
structure of the other genes, we randomly chose 76 genes from a total of 12926 genes and
calculated CCC for two groups, Eq. 1. In particular, we constructed a bootstrap sample of
all 12926 genes, and then calculated the average CCC for networks of 76 randomly chosen
genes from this bootstrap sample. The link value is the Pearson correlation coefficient for
each pair of 76 genes for two groups. We repeated the procedure 1000 times. The bootstrap
method was when used to calculate an average CCC for all genes and the standard error
of this average. The CCC for the non-metastatic patients group of 0.925 with standard
deviation 0.0125, compared to the CCC for the metastatic patients group is 0.918 with
standard deviation 0.0148. The difference for a student’s t-test is significant , p-value
= 1.05× 10−3.
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Figure 3: The tissue networks with nodes as tissues and links calculated from gene ex-
pression values. a) Link value from tissue-tissue database. b) Link value weighted by the
gene expression data from a patient from the non-metastatic outcome group. c) Link value
weighted by the gene expression data from the metastatic outcome group. Here only those
genes with the tc = 0.1 highest expression values are used.
We built a tissue-tissue network for each patient, as a function of the expression level
cutoff. Nodes are tissues, and link values are given by Eq. 2. Figure 3 shows an example
of this network for a patient from the non-metastatic outcome group and a patient from
the metastatic outcome group. Figure 3a shows the values of the links in the tissue-tissue
network, before scaling by the expression data from the breast cancer patients, i.e. li,j from
Eq. (2) with Pk,α ≡ 1. Figure 3b shows the values of the links in the tissue-tissue network for
a patient in the non-metastatic group, i.e. lki,j from Eq. (2) where k is in the non-metastatic
group. Figure 3c shows the values of the links in the tissue-tissue network for a patient in
the metastatic group, i.e. lki,j from Eq. (2) where k is in the metastatic group. Figure 4a
shows the amount of hierarchy in the tissue-tissue network with the expression level cutoff
ranging from 0.1 to 0.9 for the metastatic and non-metastatic patient groups. For each
patient, we determined the time of cancer recurrence. In typical cancer analysis, recurrence
within 5 years of surgery indicates ‘non-cure.’ More rapid relapse times are interpreted as
more aggressive cancer recurrence. Figure 4b shows the relationship between CCC and
relapse time.
The structure of the tissue-tissue network is different from that of a random network. As
with the gene network, we compared the real tissue network to a randomized network, in
which link values are randomly reassigned. The average CCC of the randomized network
in the range tc = 0.1 to 0.9 is 0.864 with standard deviation 0.017. The corresponding
average value of the real network from which Fig 4a is derived is 0.955 with standard
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Figure 4: a) The average normalized CCC calculated from the tissue-tissue network for
patients in metastatic (dashed) and non-metastatic groups (solid). The CCC for metastatic
patients is below that for non-metastatic patients. The error bars are one standard error.
The p-value for student-t test is 0.0295 for the tc = 0.1 data point and less than 0.05 for all
three tc = 0.3–0.1 data points. The insert shows the distribution of expression levels within
the tissue-tissue network. We use the highest tc fraction of these data in our analysis. b)
The correlation between CCC and relapse time in the metastatic patients. Cancer appears
a dedifferentiation on the set of all gene values, and we here observe a correlation between
shorter relapse times and lower CCC values.
deviation 0.011. The z-score is, therefore, ZCCC = 5.35, which indicates that there is
statistically significantly more hierarchy in the real tissue network than in the randomized
network
4 Discussion
The classical view of cancer is that it is a dedifferentiation of the host. A disruption of
the structure of the tissue-tissue network is, indeed, observed in Figure 4. The structure
of the network in patients with more aggressive, metastatic cancers is more disrupted than
in patients with no metastasis. Furthermore, among the metastatic patients, the structure
of the network was more disrupted in the patients with the more aggressive cancers that
recurred earlier, as seen in Fig. 4b. Both of these results are consistent with the picture
of cancer as a general dedifferentiation of the host tissue network. From the point of view
of the host, cancer is a disruption. Structure in the host network, which endows the host
with robust functioning, is destroyed by the cancer.
Thus, we expect the values of the CCC for the tissue-tissue network to be lower for patients
in the metastatic group. Figure 5a shows the distribution of the normalized CCC for each
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patient in the non-metastatic or metastatic outcome groups. We use tc = 0.1 because for
this value, there is the greatest discrimination between the metastatic and non-metastatic
populations in Figure 4a. These distributions, when averaged, give the tc = 0.1 values
in Fig 4a. The distribution of the metastatic outcome group is shifted to lower average
normalized CCC values. In addition, the width of the metastatic population distribution
is slightly larger. Figure 5b shows the probability of metastasis for a patient with a given
normalized CCC value, according to the equation
p(metastatic) =
Nmetastaticfmetastatic
Nmetastaticfmetastatic +Nnon−metastaticfnon−metastatic
(5)
HereNmetastatic = 107, andNnon−metastatic = 179. The values of fmetastatic and fnon−metastatic
are equal to the dashed and solid curves in Fig. 4a, respectively. The quantity p(metastatic)
is a biomarker. The biomarker is highly discriminating for low values of the CCC, although
only a small fraction of the patients have such low values of the CCC. For example, 5% of
the patients values are below CCC∗norm = 0.634, here for which p(metastatic) = 0.5.
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Figure 5: a) The distribution of CCC values for the non-metastatic (solid) and metastatic
(dashed) outcome patient populations. We calculated the average CCC and the standard
derivation of the CCC in the non-metastatic group and the metastatic groups. We used
the tissue-tissue networks with tc = 0.1. The resulting, Gaussian distribution fits to the
non-metastatic and metastatic groups are shown. b) The probability of metastasis for a
given patient depends on the CCC value for that patient, from Eq. (5). Lower values of
CCC are more likely to lead to metastasis. The thin horizontal line illustrates the 37.4%
probability of metastasis in the population, e.g. 107 metastatic patients, divided by 286
total patients. c) The ROC curve for the prediction that CCC < xcutoff leads to metastasis,
shown only for the 5% of the population with the smallest CCC.
We note that the standard BRCA-1 and BRCA-2 biomarkers for cancer apply to roughly
5–10% of women [29, 30]. Thus, the biomarker in Eq. 5, which applies to only 5% of the
patients, is perhaps of more significance than it may initially appear. Female subjects
with BRCA-1 biomarkers have a cumulative lifetime risk of breast cancer in the range of
50–80%, versus a background risk of 12.5% [29, 30]. The predictive power in Fig. 5b, also
> 50% for the 5% of the population with CCC < CCC∗, is, therefore, perhaps also of
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greater significance than one might initially think. The CCC may be combined with other
genetic biomarkers to achieve increased predictive power [4–12].
In Fig. 4 we find that highly expressed genes contribute more to the distinction between
structures of tissue-tissue networks in patients with metastatic and non-metastatic out-
comes. That is, highly expressed genes may have more impact on cancer outcome than
lowly expressed genes. We do find, for example, the average expression level of cancer-
associated genes is 15.25% higher than the average expression level of all genes.
One view of cancer is that it is an activation of cancer-specific pathways, perhaps hijacked
atavistic host pathways [31]. Therefore, by examining cancer-specific pathways, we should
see the development of structure in cancer patients. Figure 2 shows that the structure
of networks of cancer-associated genes is greater in patients with aggressive, metastatic
cancers than in patients with non-metastatic cancers. Cancer is an activation on the
network of cancer associated genes. Conversely, because cancer is a dedifferentiation on
the network of all genes, the CCC is lower for the entire gene network in the more aggressive
tumors of metastatic patients in Figure 4. As discussed in section 3.1, the CCC of the
gene network for randomly chosen genes is lower in the metastatic patients than in non-
metastatic patients. The results show that the network structure of cancer-associated
genes correlated with the clinical outcome. That is, metastatic tumors dedifferentiate the
structure of most genes, but build up the structure of cancer associated gene networks.
Recalculating the tissue-tissue network, Eq. (2), using only the cancer associated genes
confirms this result. Eq. (2) is used, but only for α within the 6 cancer associated genes
from [22] that are also present in the dataset of [24]. As expected, this calculation shows
the trend in Figure 4 is reversed to that of Figure 2: the CCC of the tissue-tissue network
constructed from only cancer associated genes is higher for the metastatic group than for
the non-metastatic group, with p-value 0.076.
The CCC provides a new perspective in studying the structure of cancer networks. A
higher CCC indicates a more hierarchical network, indicative of increased structure. This
increased structure often allows for greater evolvability and is often induced by environ-
mental stress [15]. Networks of cancer associated genes in metastatic patients are more
hierarchical than in non-metastatic patients.
5 Conclusion
We have defined a measure of hierarchy in cancer networks. We found a correlation be-
tween the CCC and the clinical outcome. In our study, the CCC of the cancer-associated
gene network was higher for the metastatic outcome group than for the non-metastatic
outcome group. We anticipated this result, partly because physics of evolution in changing
environments [15, 32] suggests that increased hierarchical structure helps cancer to better
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adapt to the changing environments encountered in metastasis and to overcome the natural
barriers to metastasis in the body.
We find highly expressed genes play a particularly important role in predicting the metas-
tasis of breast cancer. We found that disruption of the tissue-tissue network is correlated
with both metastatic potential and shorter time of recurrence. Cancer is a complex dis-
ease involving genetic, epigenetic, and environmental perturbations. Furthermore, cancer
operates within and between tissues. Our study of the tissue-tissue network provides
additional insights and a possible additional biomarker for breast cancer metastasis and
recurrence.
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